Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/AbbVie rated buy with strong growth and 2.7% dividend yield, ideal for market volatility diversification.
ABBV
$258.56
-$0.73 -0.28%

AbbVie rated buy with strong growth and 2.7% dividend yield, ideal for market volatility diversification.

Analyst Insights
24 Jul 2026
Seeking Alpha
View Source
Bullish
pluang ai news

AbbVie has earned a buy rating due to accelerating revenue and profit growth, supported by a reasonable valuation at 18 times forward P/E. The company offers a 2.7% forward dividend yield, outperforming its peers by 68%, and has maintained 12 consecutive years of dividend increases. Dividend growth remains a key part of AbbVie's shareholder-friendly capital strategy, with a payout ratio of 59% and expectations for continued dividend hikes. Despite recent double-digit stock price gains, AbbVie's defensive business model and steady fundamentals make it a strong candidate for portfolio diversification amid ongoing market volatility.

More News (ABBV)

Phase 3 trial of epcoritamab in relapsed/refractory DLBCL misses primary overall survival endpoint in U.S.

Phase 3 trial of epcoritamab in relapsed/refractory DLBCL misses primary overall survival endpoint in U.S.

Genmab and AbbVie announced that the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a bispecific antibody treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival (OS) in ...

Company Fundamentals
Bearish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App